Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Gout: HELP
Articles by Milica Blagojevic-Bucknall
Based on 2 articles published since 2010
(Why 2 articles?)

Between 2010 and 2020, Milica Blagojevic-Bucknall wrote the following 2 articles about Gout.
+ Citations + Abstracts
1 Article Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. 2020

Roddy, Edward / Clarkson, Kris / Blagojevic-Bucknall, Milica / Mehta, Rajnikant / Oppong, Raymond / Avery, Anthony / Hay, Elaine M / Heneghan, Carl / Hartshorne, Liz / Hooper, Julie / Hughes, Gemma / Jowett, Sue / Lewis, Martyn / Little, Paul / McCartney, Karen / Mahtani, Kamal R / Nunan, David / Santer, Miriam / Williams, Sam / Mallen, Christian D. ·Primary Care Centre Versus Arthritis; School of Primary, Community and Social Care, Keele University, Keele, UK e.roddy@keele.ac.uk. · Haywood Academic Rheumatology Centre, Midland Partnership NHS Foundation Trust, Stoke-on-Trent, UK. · Primary Care Centre Versus Arthritis; School of Primary, Community and Social Care, Keele University, Keele, UK. · Keele Clinical Trials Unit, Keele University, Keele, UK. · Birmingham Acute Care Research/Heart of England NHS Foundation Trust/Institute of Applied Health Research (BCTU), University of Birmingham, Birmingham, UK. · Health Economics, University of Birmingham, Birmingham, UK. · Division of Primary Care, University of Nottingham, Nottingham, UK. · Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. · Primary Care and Population Sciences, University of Southampton, Southampton, UK. ·Ann Rheum Dis · Pubmed #31666237.

ABSTRACT: OBJECTIVES: To compare the effectiveness and safety of naproxen and low-dose colchicine for treating gout flares in primary care. METHODS: This was a multicentre open-label randomised trial. Adults with a gout flare recruited from 100 general practices were randomised equally to naproxen 750 mg immediately then 250 mg every 8 hours for 7 days or low-dose colchicine 500 mcg three times per day for 4 days. The primary outcome was change in worst pain intensity in the last 24 hours (0-10 Numeric Rating Scale) from baseline measured daily over the first 7 days: mean change from baseline was compared between groups over days 1-7 by intention to treat. RESULTS: Between 29 January 2014 and 31 December 2015, we recruited 399 participants (naproxen n=200, colchicine n=199), of whom 349 (87.5%) completed primary outcome data at day 7. There was no significant between-group difference in average pain-change scores over days 1-7 (colchicine vs naproxen: mean difference -0.18; 95% CI -0.53 to 0.17; p=0.32). During days 1-7, diarrhoea (45.9% vs 20.0%; OR 3.31; 2.01 to 5.44) and headache (20.5% vs 10.7%; 1.92; 1.03 to 3.55) were more common in the colchicine group than the naproxen group but constipation was less common (4.8% vs 19.3%; 0.24; 0.11 to 0.54). CONCLUSION: We found no difference in pain intensity over 7 days between people with a gout flare randomised to either naproxen or low-dose colchicine. Naproxen caused fewer side effects supporting naproxen as first-line treatment for gout flares in primary care in the absence of contraindications. TRIAL REGISTRATION NUMBER: ISRCTN (69836939), clinicaltrials.gov (NCT01994226), EudraCT (2013-001354-95).

2 Article The Risk of Gout Among Patients With Sleep Apnea: A Matched Cohort Study. 2019

Blagojevic-Bucknall, Milica / Mallen, Christian / Muller, Sara / Hayward, Richard / West, Sophie / Choi, Hyon / Roddy, Edward. ·Keele University, Arthritis Research UK Primary Care Centre, Research Institute for Primary Care & Health Services, Newcastle-under-Lyme, Staffordshire, UK. · Newcastle University, Freeman Hospital, Newcastle upon Tyne, UK. · Massachusetts General Hospital, Boston. ·Arthritis Rheumatol · Pubmed #30160059.

ABSTRACT: OBJECTIVE: Obstructive sleep apnea (OSA) is associated with a range of serious comorbidities. This study was undertaken to investigate whether people with OSA are more likely to develop gout, in the short and long term, compared to those without OSA. METHODS: A matched retrospective cohort study was undertaken using the UK Clinical Practice Research Datalink. Individuals age ≥18 years who received a diagnosis of OSA between 1990 and 2010 were identified and matched on age, sex, and practice with up to 4 individuals without OSA; follow-up was until the end of 2015. Hazard ratios (HRs) were estimated using Cox regression adjusted for general health, lifestyle, and comorbidity characteristics. The risk of developing gout was assessed at different time points, and the body mass index (BMI) category-specific results were presented. RESULTS: The study sample included 15,879 patients with OSA and 63,296 without. The median follow-up was 5.8 years. We found that 4.9% of patients with OSA and 2.6% of patients without the disorder developed gout. The incidence rate per 1,000 person-years was 7.83 (95% confidence interval [95% CI] 7.29-8.40) and 4.03 (95% CI 3.84-4.23) among those with and without OSA, respectively. The adjusted HR was 1.42 (95% CI 1.29-1.56). The risk of developing gout among OSA patients compared to those without was highest 1-2 years after the index date (HR 1.64 [95% CI 1.30-2.06]). This finding persisted among those who were overweight and obese. For those with normal BMI, the highest significant HR (2.02 [95% CI 1.13-3.62]) was observed at 2-5 years after the index date. CONCLUSION: In this study, patients with OSA continued to be at higher risk of developing gout beyond the first year following the diagnosis. Our results further indicate that peak incidences of gout vary according to BMI.